Black Licorice: The Game-Changer for IBD Sufferers

A compound extracted from black licorice root has emerged as a potential breakthrough treatment for inflammatory bowel disease, offering hope to millions who suffer from conditions that current therapies often fail to adequately control.

Story Snapshot

Researchers at the University of Tokyo screened approximately 3,500 compounds using human stem cell-derived intestinal models to identify protective agents against inflammatory bowel disease
Glycyrrhizin, a natural compound from black licorice root, emerged as the top candidate for protecting intestinal cells from tumor necrosis factor-induced cell death
The study utilized cutting-edge organoid technology, creating miniature human intestines from stem cells to test therapeutic compounds in a more realistic biological environment
This discovery could lead to safer, more effective treatments for Crohn’s disease and ulcerative colitis, conditions affecting millions worldwide

The Science Behind the Sweet Discovery

The University of Tokyo research team faced a significant challenge: how to test thousands of potential IBD treatments without relying solely on animal models that often fail to predict human responses. Their solution involved creating organoids, miniature intestinal structures grown from human stem cells that mimic the actual human gut environment. These organoids provided a platform to screen compounds against tumor necrosis factor, a protein that triggers the inflammatory cascade responsible for much of the tissue damage in IBD. Out of 3,500 tested compounds, glycyrrhizin consistently demonstrated superior protective effects.

Why Current IBD Treatments Fall Short

Inflammatory bowel disease encompasses primarily Crohn’s disease and ulcerative colitis, chronic conditions characterized by debilitating inflammation of the digestive tract. Current treatment approaches rely heavily on immunosuppressants and biologics that target TNF, yet these medications come with significant drawbacks. Many patients experience incomplete symptom relief, while others develop resistance over time. The side effects range from increased infection risk to potential malignancies, creating a treatment landscape where patients often choose between ongoing suffering and accepting substantial health risks. This gap in effective, tolerable therapies makes the glycyrrhizin findings particularly significant.

From Ancient Remedy to Modern Medicine

Glycyrrhiza glabra, the scientific name for the licorice plant, has been employed in traditional medicine for thousands of years across multiple cultures. Ancient practitioners recognized its anti-inflammatory properties long before modern science could explain the mechanisms. What makes this research compelling is the marriage of ancient botanical wisdom with contemporary stem cell technology. The compound’s natural origin suggests potentially fewer synthetic side effects compared to engineered pharmaceuticals, though rigorous clinical trials will determine its true safety profile. The irony that a candy flavoring could become a serious medical treatment is not lost on researchers.

The Organoid Revolution in Drug Discovery

The methodology employed in this study represents a paradigm shift in how scientists approach drug development. Traditional pharmaceutical research has long relied on animal testing, which frequently fails to translate to human efficacy. Organoids bridge this gap by providing human tissue models that respond more predictably to treatments. These miniature organs, grown in laboratory dishes, replicate the cellular diversity and structural organization of actual human intestines. The technology allows researchers to observe in real-time how compounds interact with human cells, dramatically accelerating the discovery process while reducing dependence on animal subjects and lowering research costs.

Black licorice compound shows promise against inflammatory bowel disease

Researchers have developed a stem cell-based model of the human intestine that may transform how new IBD treatments are discovered. After testing thousands of compounds, they identified glycyrrhizin — a…

— The Something Guy 🇿🇦 (@thesomethingguy) May 10, 2026

The path from laboratory discovery to pharmacy shelf remains long and uncertain. Glycyrrhizin must now undergo rigorous clinical trials to establish appropriate dosing, confirm efficacy in living patients, and identify any unforeseen complications. The compound’s existing use in some traditional medicines and food products provides encouraging preliminary safety data, but medical-grade formulations require substantially higher standards of proof. Researchers acknowledge that years of testing lie ahead before glycyrrhizin-based IBD treatments could receive regulatory approval. For patients currently managing these debilitating conditions, this discovery offers genuine hope grounded in solid science rather than empty promises.